Compare iShares Self-Driving EV and Tech (IDRV) vs Moderna, Inc. (MRNA) Price & Performance

IDRV trades at $35.67, down 1.22% with a bearish technical outlook as moving averages signal strong selling pressure. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026, providing income potential amid market volatility.

The stock faces headwinds from technical weakness and competitive EV market dynamics. Upside depends on broader EV adoption trends and company-specific execution, while risks include regulatory changes and economic pressures. Investors should weigh the bearish signals against long-term sector growth opportunities.

Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.

The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.